The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials
-
- Daida Hiroyuki
- Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine
-
- Dohi Tomotaka
- Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine
-
- Fukushima Yoshifumi
- Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine
-
- Ohmura Hirotoshi
- Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine
-
- Miyauchi Katsumi
- Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine
この論文をさがす
抄録
<p>Enormous effort has been put into the prevention of atherosclerosis through risk modification, especially with lipid-lowering therapies. Regression, that is, the reversal of the atherosclerosis process, has long been a goal of atherosclerosis research among basic and clinical investigators. Intravascular ultrasound (IVUS) was developed in the 1990s as an intracoronary imaging technique to observe the details of the vessel walls and to measure the vessel lumen and plaque area with high reproducibility. Compared with the coronary angiogram, IVUS provides far more detailed information on the vessel wall. In this article, we review lipid-lowering trials that have used IVUS and discuss the current understanding of the effectiveness of aggressive lipid-lowering therapy, which inhibits atherosclerotic progression and induces regression and plaque stabilization.</p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ
-
Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ 26 (7), 592-600, 2019-07-01
一般社団法人 日本動脈硬化学会
